TetraLogic Pharmaceuticals Corporation
TLOG
$0.00
$0.000.00%
OTC PK
| 09/30/2016 | 06/30/2016 | 03/31/2016 | 12/31/2015 | 09/30/2015 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -17.22% | -8.74% | -5.36% | 1.57% | -6.01% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -43.84% | -24.84% | 0.08% | 23.34% | 30.31% |
| Operating Income | 43.84% | 24.84% | -0.08% | -23.34% | -30.31% |
| Income Before Tax | 9.19% | 6.21% | -11.08% | -38.28% | -54.51% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 14.08% | 6.21% | -11.08% | -38.28% | -54.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.08% | 6.21% | -11.08% | -38.28% | -54.51% |
| EBIT | 43.84% | 24.84% | -0.08% | -23.34% | -30.31% |
| EBITDA | 43.98% | 25.01% | 0.10% | -23.24% | -30.10% |
| EPS Basic | 20.10% | 13.18% | -3.10% | -30.09% | 16.04% |
| Normalized Basic EPS | 39.73% | 22.97% | 5.61% | -19.68% | 14.35% |
| EPS Diluted | 20.08% | 13.43% | -3.16% | -28.93% | 16.51% |
| Normalized Diluted EPS | 39.66% | 22.90% | 5.53% | -19.75% | 14.35% |
| Average Basic Shares Outstanding | 7.36% | 8.13% | 7.79% | 6.28% | 27.85% |
| Average Diluted Shares Outstanding | 7.22% | 8.00% | 7.67% | 6.18% | 27.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |